The Christ Hospital Launched CRISPR Cholesterol Trial

Cincinnati researchers have initiated a clinical trial testing a gene-editing therapy designed to lower high cholesterol.

Updated on Oct. 14, 2026 in Biotech

The Christ Hospital Launched CRISPR Cholesterol Trial

Live Poll

Would you trust experimental gene-editing therapies to manage your long-term health risks?

The Christ Hospital has launched a new clinical trial utilizing the CRISPR-based treatment VERVE-201 to target high cholesterol. This gene-editing therapy aims to offer a permanent solution for patients who have not responded to standard medical interventions.

Why it matters

The trial addresses a critical need for patients with cholesterol levels resistant to traditional medications by attempting to provide a permanent genetic fix. This approach could fundamentally change how chronic cardiovascular conditions are managed at the biological level.

The VERVE-201 treatment utilizes CRISPR-Cas9 technology to modify DNA and reduce liver production of LDL cholesterol and lipoprotein A. Participants are monitored over 15 years through recurring blood tests and overnight clinical stays.

The players

The Christ Hospital

This is a Cincinnati-based healthcare facility currently serving as the site for the new gene-editing clinical trial.

The details

Administered via a single infusion, the therapy works by cutting DNA strands to alter genetics associated with high cholesterol production. This method builds on previous findings where a single infusion successfully maintained lowered LDL levels for at least two years.

The clinical trial officially launched at The Christ Hospital on October 14, 2026.

The Tech Race

This trial follows the broader expansion of the CRISPR-Cas9 gene-editing platform into the treatment of non-hereditary chronic metabolic diseases. It positions this therapeutic approach as a potential successor to traditional daily pharmacological management for cardiovascular health.

For patients suffering from cholesterol resistant to traditional medication, this trial represents a potential move toward one-time genetic treatments. Participants in the study will undergo rigorous, long-term monitoring including periodic overnight stays and blood work.

The takeaway

This trial marks a significant shift in cardiovascular care by targeting the genetic root of cholesterol production rather than just managing symptoms. Patients who have struggled with medication resistance may eventually find relief through these permanent, infusion-based therapies.